Alizyme Share Discussion Threads

[troutfish] 03/6/2009 09:25

Yeh and tell Mr McCarthy to cut some more off his salary.

[chronicler] 03/6/2009 08:46

seven wonders why not try to contact alizyme to try to clarify that point..

[chronicler] 02/6/2009 13:50

If a Co is not a going concern it gets delisted from the full Stock Market.

AZM should be alright through to the end of 2010 but get cash before then from the Takeda Phase 3 Cetilistat results and posooibly something from Prometheus on Colalpred Phase 3 in the United States. Something should come of Colalpred for the active disease out of the current discussions with the European regulators.

[dunderheed] 02/6/2009 13:22

No likely we are not paying for DT service.

[corsondav] 02/6/2009 13:00

A) We don't have any real oncology product except atl whatever.
B) As everone knows are management certainly aren't delusional.
On a more srious note: anyone noticed that the D>Telegraph have delisted us under pharmas? I don't know if cos have to pay to be in a paper's SE listings but I hope this dosen't augur a delisting from se.

[loafofbread] 01/6/2009 21:29

Takeda's Millennium Looking For Deals To Bolster Pipeline





By Thomas Gryta
Of DOW JONES NEWSWIRES

ORLANDO -(Dow Jones)- It has been only a year since Japan's Takeda Pharmaceutical Co. (4502.TO) bought Millennium Pharmaceuticals for $8.8 billion, but now the Cambridge, Mass., biotech is looking to make deals of its own.

Takeda is Japan's biggest drug maker by sales, and Millennium heads their global oncology operations with 14 candidates in the combined pipeline. Those are in early development, and Millennium Chief Executive Deborah Dunshire is looking for deals to add mid-stage and late-stage compounds - but notes some drug makers refuse to accept that depressed market valuations are here to stay.

"I don't see us acquiring a very large company," she said in an interview at the American Society of Clinical Oncology annual meeting in Orlando. She noted Takeda would avoid deals such as Pfizer Inc.'s (PFE) pending $68 billion buy of Wyeth (WYE) because they don't create value for shareholders over the long run.

"It will probably be smaller, single product acquisitions," she said, but noted it's possible they could make a larger transaction in the $10 billion range.

Millennium has maintained its independence within Takeda and was the driving force behind the recent buy of IDM Pharma Inc. (IDMI) for $75 million, Dunshire said.

Millennium's flagship product is Velcade, a blood cancer treatment sold with Johnson & Johnson (JNJ) that had global sales of more than $1 billion in 2008.

Dunshire is open-minded when considering deals, and is using the ASCO meeting to talk to potential partners or acquisition targets, but declined to name specific companies.

Though the economy and difficult funding environment has depressed the valuations of small drug developers across the board, Dunshire said it doesn't necessarily mean companies can be bought at cheaper valuations.

"Some of the companies out there may have depressed valuations, but their boards are not willing to accept a premium over that low valuation," she said.

Dunshire said some companies believe they can weather the financial storm, but have overly optimistic estimates of a drug's potential use and pricing.

"There have been certain deals that we've looked at, where the company had valuations in mind that we just didn't think the product could support," she said.

She believes the stock market has permanently reset its views toward smaller drug companies - something executives for former high-flyers may have a hard time accepting. However, Dunshire admits there is probably something more at work.

"They probably are delusional that [their valuation] is going to get back to exactly where it was before, but there is a down draft that may have nothing to do with the fundamentals of their company," Dunshire said.

[chronicler] 30/5/2009 19:31

The results of Norgenes European Phase 3 trial said "There was no clinically relevant difference in response in terms of efficacy, safety and tolerability across the three COLAL*PRED® treatment groups (40 mg, 60 mg or 80 mg o.d.), supporting a dose recommendation of 40 mg o.d" so it seems obvious TSD would opt for a "single dose study" as their website says - probably at the lower dose level - and that it seems it has completed alright according to TSD's website.

You would think completion of the Japanese Phase 1 trial would be price sensitive info alizyme should have mentioned last November and got right in a Management Statement six months after.


PS If the lowest dose of 40mg gives some statstically significant efficacy without safety or tolerability issues I assume that increases the chances of colalpred being used in the maintenance of remission where dosing has to be maintained longterm.

[seven wonders] 30/5/2009 11:42

Can someone please clarify:

TSD's website R&D page says of COLAL-PRED [TSD-0011]:

"As of November 2008, Phase I Single Dose study was completed".

and in the Products table at the bottom of the page:

"Phase l
completed"




- So what were the results for this single dose study?

- And why does Alizymes Interim Management Statement 19/5/2009 still talk about:

"TSD Japan Inc, Alizyme's partner in Japan, is progressing a Phase I study in Japan".

if TSD are saying Phase 1 was completed six months ago?

[psyco] 29/5/2009 14:44

chronicler > many thanks agree , now ive got many shares at 6p , would have cost me 100s of thousands pounds a year ago , will be topping up , if it goes bust , it goes bust , :-)))

[chronicler] 29/5/2009 12:34

I dont see any harm in rejecting the remuneration report as it will save money but i dont see any point in getting rid of the CEO.

In some ways I am glad they have had a bit of bad luck because it provides a lower entry point and more upside from anything good that arises from the current Phase 3 Takeda Cetilistat Japan trial or anything else that moves forward.

[troutfish] 29/5/2009 12:29

McCarthy has taken a voluntary 30% salary cut. :-)

[troutfish] 29/5/2009 12:27

Moved to the other thread.

[peaeff] 29/5/2009 11:27

SSG

My apologies for being a tad flippant, but I feel sure that the October 2007 forecasts made by TM had nothing to do with Northern Rock. When the real sh.. hit the fan the deals should have been safe and secure by his timing, and in any case, IMO, the credit crunch has nothing to do with signing of deals in this particular industry.

Any large pharma could buy this company for peanuts. No need to step aside there's no rush.

Regards

[dunderheed] 29/5/2009 11:02

I agree chronic except for one thing - the thing is - 'mgt' have promised deals for RoW - if this is not forthcoming then a change of heads is certainly needed because they obviously have not come up with the goods.
Therefore everything to say is reasonable except for the question mark over 'mgt'.

[chronicler] 29/5/2009 10:58

cetilistat in japan is the main thing that interests me at present with Alizyme and for that the deal has already been done with Takeda and like I said earlier the Phase 3 trial ends July 2010 and could make Alizyme a 10 to 15 bagger from this level.

also like I said these little companys sit around for years with the shares in the doldrums but all it takes is one spark and they are off like rockets.

On the "promises of deals" they have recently done three deals for Colalpred with Norgine, Prometheus and TSD, covering Europe, North America and Japan.

If anything else comes of Colalpred, a rest of world deal for cetilistat, or ATL104, I will treat it as a bonus and the posssibility is also there as a safety net.

I think the strategy on ATL104 is they want to progress it as far as possible themselves, hence no deal so far, but they would do a deal if all else fails.

But as i said Cetilistat Japan is my main interest here and for that the deal is already done and Phase III is in progress.

[silverbackalpha] 29/5/2009 10:40

blah blah blah

It "could" build a space shuttle to jupiter, but will it?

Promises of deals have been outstanding for over 3 years, and nothing tangible coming through. Now, as a casual observer: would you say something was likely under those conditions?

[chronicler] 29/5/2009 10:04

psyco alizymes share price could easily be a 10 to 15 bagger next year from this level if the japanese Phase 3 results in July 2010 are OK.

These little companys sit around for years with the shares in the doldrums but all it takes is one spark and they are off like rockets.


psyco - 29 May'09 - 08:05 - 23629 of 23630

Assuming celistat is a success what will be the value to azm compared to sales of alli, anyone ?

[dunderheed] 29/5/2009 08:14

alli is otc thus not really comparable - as I assume massive marketing spend which must cut into margins?
Let's just get RoW (I assume re Alli reference) sorted prior to talking sales volumes - this is the factor that will determine whether the Tim can cut it and whether his tenure will remain!!

[psyco] 29/5/2009 08:05

Assuming celistat is a success what will be the value to azm compared to sales of alli, anyone ?

[silent cartographer] 29/5/2009 00:04

Who woke up the Gimp ?

[silverbackalpha] 29/5/2009 00:02

Peaff: its what happened ok. Its done now, but thats what happened.

[seagullsslimjim] 28/5/2009 19:54

Credit crunch started Autumn 2007 with Northern Rock

[peaeff] 28/5/2009 11:43

Silver

The credit crunch hadn't been invented at Christmas 2007 when all the deals were to be done.

[peaeff] 28/5/2009 11:41

Chronicler

I cannot fault your arguments except to say this. When the last collection took place they were secure in the knowledge that funding was, for the foreseeable future secured. There was no chance at that time that any accounting aspects might enter into the equation. Now there is. It's become a race against time but not in respect of how quickly products can get to market but how long it will be before the cash runs out. The answer to that problem is not in the hands of management but in the hands of others.

Accepting, as I do, that there is no sentiment in business, why should any of those who could help AZM stay in business, those who will pass on milestones, make any extra effort to ensure that doesn't happen. Takeda have now taken 6 years to reach an early phaseIII level with Ceti. (maybe not their fault necessarly) and even more proving of the point is the fact that it has stood still over here for 2+ years, stagnant through lack of funding which, once again, will have to rely on others to provide.

So far there has been no rush to do do. It is easy in hindsight to comment but if I had thought for one moment back in 2003 that this company would not have progressed beyong this stage by now, I would have a few more thousands in the bank.

Paragraphs such as those written by TM planning to transform this company into a future developing pharma take wishful thinking to another level.

There is one other aspect which fascinates me. Should Takeda successfully market Ceti. in Japan, after their phaseIII trials, and there are still no deals in place for RoW, how will that reflect upon, and be construed by, the worlds drug companies who are supposedly desparate for new products and, with governments particularly focussed on obesity.

Something, somewhere, just isn't right.

Regards